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The absorption of dietary phosphorus and calcium in hemodialysis
patients. Absorption of dietary phosphorus plays a critical role in the
development of metabolic bone diseases in patients with chronic renal
failure. However, phosphorus absorption is difficult to quantitate in
dialysis patients because the dialysis treatments complicate metabolic
balance studies. Utilizing a recently developed technique which permits
measurement of net absorption of dietary constituents after a single
meal, we measured phosphorus absorption in dialysis patients. The
following observations were made: A.) Following a meal containing
approximately 300 mg phosphorus, mean phosphorus absorption in five
hemodialysis patients (with severe vitamin D deficiency) was only
slightly less than in matched controls (186 35 vs. 242 30). B.) After
dialysis patients were treated with 1 ,25(OH)2.D3, phosphorus absorp-
tion increased from 186 35 to 272 16 mg (P < 0.025). C.) The effect
of three aluminum containing antacids on phosphorus absorption was
studied; each slightly reduced the absorption of phosphorus compared
to placebo (P < 0.01), but there was no significant difference between
them. D.) Aluminum hydroxide and calcium carbonate each reduced
dietary phosphorus absorption to approximately the same extent.
Calcium carbonate ingestion was associated with sharply increased
calcium absorption. The absorption of dietary phosphorus is influenced
only modestly by I ,25(OH)2-D3 and is inhibited to an equal but only
modest degree by various aluminum antacids and by calcium carbonate.
The retention of dietary phosphorus is largely responsible for
the osteodystrophy and secondary hyperparathyroidism which
occurs in patients with chronic renal failure [1—5]. This has
generated considerable interest in the physiology of gastroin-
testinal phosphorus absorption and in methods to block phos-
phorus absorption in patients with chronic renal failure. In the
past, dietary phosphorus absorption was primarily studied by
the metabolic balance method. However, such methods require
the patient to spend weeks to months in a balance ward, and
accurate measurements of ingested and excreted phosphorus
are necessary if meaningful results are to be obtained. There-
fore, only a few such studies have been carried out in patients
with chronic renal disease.
Using a method whereby absorption of dietary constituents
can be measured after a single meal, we have studied phospho-
rus absorption in dialysis patients in three experiments: a)
before and after treatment with 1 ,25-dihydroxyvitamin D3, b)
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with and without the ingestion of three aluminum containing
antacids acting as phosphorus binders, and c) with calcium
carbonate as a phosphorus binding agent.
Methods
Subjects
We studied ten adult patients with chronic renal failure who
were being treated with chronic maintenance hemodialysis.
Seven patients were men, three were women; their ages ranged
from 26 to 70 years (44 4 sEM). All patients were dialyzed
three times weekly for periods of about four hours. All were
medically stable and without overt clinical manifestations of
metabolic bone disease. Representative data from each of the
subjects is displayed on Table 1. No patient had received any
vitamin D preparation for at least six months prior to the study.
No patient had undergone nephrectomy or parathyroidectomy.
The biochemical profile of each patient was consistent with
significant phosphate retention and secondary hyperpara-
thyroidism. Seven normal subjects, matched for age, sex and
race, were also studied.
This research was approved by the Institutional Review
Board for Human Protection of Baylor University Medical
Center. All subjects were paid a fee for taking part in these
experiments. Informed written consent was obtained from each
subject.
Phosphorus absorption
The method, previously applied to absorption of dietary
calcium in normal subjects, has been described in detail [6].
Briefly, it began with a preparatory washout wherein the
subject's entire gastrointestinal tract was cleansed by lavage
with a poorly absorbable, phosphate—free, electrolyte—mannitol
solution [7]. Four hours later a meal containing 10 g polyethyl-
ene glycol (PEG) as a nonabsorbable marker was ingested.
Twelve hours after the meal, the intestine was cleansed again
by a second lavage washout, lasting four hours. The rectal
effluent from this second lavage was combined with any stool
(usually none) which had been excreted since consumption of
the meal. The meal and rectal effluent were analyzed for
phosphorus. The completeness of collection was evaluated by
recovery of the nonabsorbable marker (PEG). On a separate
day, the identical procedure was again performed, except that
the meal was omitted and in its place only water containing the
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Experiment
A. Phosphorus absorption before and after
treatment with 1 ,25(OH)rD
B. Effect of aluminum—containing antacids
Mineral content of meal'
Calciom Phosphorus
tug tug Meal constituents
308 -- 2 140 g ground sirloin, 45 g swiss cheese, 100 g
(294—323) french fried potatoes
349 ÷ 3 60 g ground sirloin, 30 g lettuce, 30 g swiss
(344—359) cheese. 1 slice bread. 30 ml french dressing320 5 60 g ground sirloin, 30 g lettuce, 30 g swiss
(305—344) cheese, I slice bread, 30 ml french dressing
0 Each meal was given with 250 ml of water which contained 10 g PEG (polyethylene glycol) as a nonabsorbable recovery marker
Results shown as mean + 5EM and range
nonabsorbable marker (PEG) was ingested; this provided an
estimate of the phosphorus appearing in the rectal effluent that
was not attributable to the ingested meal.
Net phosphorus absorption was calculated according to the
following equation: Net phosphorus absorption — phosphorus
ingested - (effluent phosphorus after meat — effluent phospho-
rus after fast). For example, assume that on test day 1,
following the preparatory washout the subject ingests a meal
containing 300 mg of phosphorus, and the final rectal effluent
washout contains 100 mg of phosphorus. On test day 2, the
subject fasts following the preparatory washout, and the final
effluent washout contains 20 mg of phosphorus, Substituting in
the equation, net phosphorus absorption — 300 — (100 — 20) =
220 mg.
Test meals
Duplicate meals were prepared on each test day, one to be
ingested by the subject and the other to be analyzed for
phosphorus. The mineral and constituent content for the meals
is shown in Table 2. The variations in the measured calcium and
phosphorus content of the meals may be due to the time lapse
between experiments (approximately two years) and changes in
commercially prepared cheese, dressing and sirloin.
Vitamin D therapy
During the phase of the study in which we analyzed the
effects of vitamin D on phosphorus absorption, calcitriol cap-
sules (Rocaltrol®, Roche Laboratories, Nutley, New Jersey,
USA) was administered to the patients with chronic renal
failure. A total of 2 g per day was administered in divided
doses for three weeks. The phosphorus absorption studies were
carried out during the final ten to twelve days of this period.
Vitamin D therapy was not utilized during the other phases of
this study and was not administered to normal subjects.
Aluminum and calcium phosphate bindei.,
Comparable doses of aluminum hydroxide (Dialumea,
Armour Pharmaceutical Co., Tarrytown, New York, USA),
aluminum carbonate capsules (Basaljel®, Wyeth Laboratories,
Philadelphia, Pennsylvania, USA), aluminum carbonate sus-
pension (Basaljel®) and calcium carbonate powder were stud-
ied. Each of these preparations was administered at a dose of 75
mEq of aluminum or calcium, as shown in Table 3. The 75 mEq
dose was derived using two quantative methods which yielded
similar results. First, the aluminum content of each preparation
was measured using atomic absorption spectroscopy. Alumi-
num weight was converted to mEq using an equivalent weight
of 9 mg/mEq. The mEq of alkali in each preparation was then
measured using an acid back titration. There was excellent
correlation between these methods. Attempts to derive the
aluminum content of these preparations from knowledge of
their weight and presumed chemical formula will be in error
because these alkali aluminum compounds form a variety of
poorly—defined chemical complexes (that is, one cannot assume
Patient
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Table 1. Clinical profile of patients with end—stage renal disease on hemodialysis
Sex/age
Duration on
dialysis
Months
Serum
phosphorus
mg/dl
9.4
Serum
calcium
mg/dl
F 52 72 10.3
M 49 19 6.7 9.8
M 38 6 8.3 8.8
M 30 48 5.8 9.1
M 44 78 6.7 9.8
F 31 75 8.2 9.1
M 70 27 7.0 9.3
F 50 32 5.8 10.6
M 53 22 7.3 8,8
M 26 12 5.9 9.5
44±4 39±9 7.1±0.4 9.5±0.2
Serum PTH
2
3
4
5
6
7
8
9
10
Mean 5EM
0 N—terminal PTH measured in pg/mi, normal: 11 to 24 pg/mI
C— terminal PTH measured in dEq/ml, normal: 40 to 100 piEq/ml
Table 2. Mineral content and constituents of each experimental meal0
3780
930
21 oa
1230
3300
9535
633
644k
759b
4o5
227 560
678 894-
C. Effect of calcium carbonate versus
aluminum carbonate
302 1
(296—316)290 3
(284—298)
268 12
(227—294)
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Table 3. Phosphate binding antacids
Phosphate
binder
Brand name
of product Form Dose
Weight
of dose
g
Aluminum/calcium
of dose
mEq
Aluminum Dialume Capsule 5 caps 30 75
hydroxide
Aluminum Basaljel Capsule 4 caps 3.4 76
carbonate
Aluminum Basaljel Suspension 25 ml 25.5 75
carbonate
Calcium — Powder — 3.75 75
carbonate
a Based on five separate determinations on lot numbers actually in the experiments shown in Figure 2. The aluminum content was measured by
atomic absorption spectroscopy and confirmed by acid back titration.
that the aluminum hydroxide in Dialume has a molecular
formula of Al(OH)3 and molecular weight of 78 mg/mEq). The
measured aluminum content was consistent with the aluminum
contents reported by Wyeth and Armour for these products.
The calcium carbonate powder was weighed and mEq content
was also confirmed by acid titration.
Analysis of samples
The duplicate test meals and rectal effluent were weighed and
then well homogenized in a Waring commercial blender. Ho-
mogenized samples were analyzed (in triplicate) for PEG by the
method of Hyden [81 and phosphorus (in duplicate) by the
method of Fiske and Subbarow [9]. Calcium was analyzed (in
duplicate) by atomic absorption spectroscopy. Serum calcium
and phosphorus were analyzed (in duplicate) by standard
clinical methods. Measurement of N-Terminal and C-Terminal
parathyroid hormone and I ,25-dihydroxyvitamin D were ana-
lyzed by the Nichols Institute, San Juan Capistrano, California,
USA. During the period of calcitriol therapy, serum for analysis
was obtained two to three hours after ingestion of the morning
dose of calcitriol.
Results
Preliminary studies on timed recovery of phosphorus and
PEG
In five subjects (three dialysis patients and two normal
subjects), the final washout fluid was collected in thirty minute
samples, each of which was analyzed for phosphorus and PEG
(Fig. 1). When subjects had not eaten the test meal (but ingested
water containing PEG), all of the PEG was recovered in the first
two hours. The phosphorus content of the washout fluid was
highest in the second thirty—minute sample, and thereafter
became fairly constant at about 4 mg per 30 minutes.
When the test meal containing 349 mg phosphorus (meal B in
Table 2) had been eaten, much more phosphorus was recovered
during the second, third, and fourth 30 minute periods. There-
after, phosphorus in the washout averaged about 4 mg per 30
minutes, similar to the phosphorus content in the latter part of
the washout following a fast.
These results indicate that all unabsorbed dietary phosphorus
is recovered within the first two hours of the washout. Phos-
phorus contained in the latter washout samples probably rep-
resent nondietary phosphorus, since it is present in equal
After meal
2 3 4
After fast
80
0,
6040
I
0 41" O..._o___O—O
1 2 3 4
Time, hr
Fig. 1. Quantitative phosphate (0) and PEG (•) recovery over time
from the rectal effluent after fasting and after a meal. Each data point
represents recovery over the preceding 30 minutes.
amounts whether or not the subjects had eaten. Presumably,
phosphorus recovered in these latter samples has diffused from
blood to gut lumen during the lavage with an initially phosphor-
us—free solution. (Note: this does not represent "endogenous"
phosphorus since digestive secretions are not stimulated by the
lavage.) In any case, these studies indicate that unabsorbed
dietary phosphorus will be recovered by a four hour washout,
which was the standard washout period used in all our studies.
Phosphorus absorption in normal subjects and in dialysis
patients before and after treatment with 1,25(OH)2-D3
Prior to vitamin D therapy, each patient was studied twice,
after a meal and after a fast. The order of tests (fast vs. meal)
was randomized. Patients were then treated with oral calcitriol
capsules as described in Methods. Five dialysis patients (Table
1, patients ito 5), and five normal control subjects, matched for
age, sex and race, were studied. The content of the test meal is
shown in Table 2 (meal A).
Individual results and group averages are shown in Table 4.
PEG recovery in all three groups was excellent with a mean
recovery of 99% (range 86 to 102%). When meals containing
about 300 mg of phosphorus were eaten by normal subjects,
intestinal lavage twelve hours later resulted in recovery of an
average of 68 mg of phosphorus. Phosphorus recovery after a
fast was only 7 mg in normal subjects. Therefore, the lavage
procedure itself can account for only a small amount of the
phosphorus recovered after a meal; the remainder must repre-
sent unabsorbed dietary phosphorus or phosphorus contained
in digestive secretions evoked by the meal. From these results
we calculate (see Methods) that normal subjects absorbed an
average of 242 mg of phosphorus after ingesting a 303 mg
phosphorus meal (80%).
In the vitamin D deficient dialysis patients, phosphorus
recovery after a fast averaged 22 mg, which was significantly
higher than the 7 mg recovered in normal subjects. Thus, the
lavage procedure itself causes somewhat more phosphorus
recovery in dialysis patients compared to normals. This is
possibly due to less efficient reabsorption of phosphorus which
has diffused into the lumen during lavage. In addition, the
dialysis patients had a higher serum phosphorus concentration
producing a larger blood to lumen gradient for phosphorus
diffusion. After ingestion of the meal containing an average of
308 mg of phosphorus, the dialysis patients absorbed 186 mg
phosphorus (60% of intake). Although this average result is less
than that found in normal subjects, the difference was not
statistically significant. After treatment of the dialysis patients
with calcitriol, the serum 1 ,25(OH)2-D3 level was increased to
95 14 pg/mI, and mean phosphorus absorption increased to
272 mg (86% of intake). This was not different than phosphorus
absorption in normal controls, but it was significantly higher
than the phosphorus absorption in dialysis patients before
vitamin D therapy (P C 0.05).
Effect of aluminum antacids on dietary phosphorus
absorption
Three aluminum antacid preparations are shown in Table 3.
The total dose was ingested immediately before the subjects
began to eat the test meal.
Seven dialysis patients (Table I, patients 4 to 10) were
studied. The test meal contained 290 mg of calcium and 349 mg
of phosphorus (Table 2, meal B). Each patient was studied on
five test days; a) fast; b) meal with placebo; c) meal plus
aluminum hydroxide capsules; d) meal plus aluminum carbon-
ate capsules; and e) meal plus aluminum carbonate suspension.
The order of testing was randomized.
As shown in Figure 2, after ingestion of the meal with
placebo, 245 mg (70%) of the dietary phosphorus was absorbed.
Each aluminum preparation reduced the absorption of phospho-
rus by about 100 mg (P C 0.01 for each preparation). There was
no statistically significant difference among the three aluminum
preparations as to their effect on phosphorus absorption.
Effect of calcium carbonate versus aluminum hydroxide on
dietary phosphorus absorption
The effect of aluminum hydroxide capsules and calcium
carbonate powder (analytical reagent grade) was compared.
Each was administered in a dose of 75 mEq, immediately prior
to ingestion of the meal (Table 2, Meal C). Five dialysis patients
(Table 1, patients ito 5) were studied on three test days: a) meal
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Table 4. Phosphorus absorption, PEG recovery, and serum l,25(OH)2-D3 levels in normal subjects (matched controls) and in dialysis patients
before and after I ,25(OH)rD3 treatment
Phosphorus recovery PEG recoveryNet
Phosphoru? after after Phosphorus after after Serum
Intake fast meal absorption fast meal I ,25(OH)rD3
(mg) my mg mg % % pg/mt
Matched controls
1 313 7 100 220 102 100 44
2 298 2 151 149 93 86 41
3 294 6 72 228 100 97 49
4 300 12 15 297 102 100 65
5 310 10 4 316 100 102 42
mean±5EM 303±4 7±2 68±27 242±30 99±2 97±3 48±4
Dialysis patients before
vitamin D
1 314 7 103 218 99 101 11
2 301 18 66 253 99 97 12
3 301 28 73 256 99 100 8
4 310 37 224 123 102 101 0
5 315 22 255 82 100 101 6
mean±seM 308±3 22±5c 144±40 186±35 100±2 100±1 7±2
Dialysis patients after
vitamin D
1 303 8 8 303 102 97 79
2 323 3 51 275 97 97 117
3 323 4 29 298 100 99 88
4 319 21 68 272 98 132
5 306 40 133 213 98 102 53
Mean±5EM 315±4 15±7 58±2! 27216d 99±1 99±1 94±14e
a Estimated from analysis of meal prepared in duplicate
PEG inadvertently omitted from test meal
P C 0.05 compared to matched controls
ci P c 0.05 comparing dialysis patients before and after vitamin D therapy
P C 0.01 comparing dialysis patients before and after vitamin D therapy
Phosphorus and calcium absorption in dialysis 757
*
(49%)
(38%)
(20%)
(14%)
plus placebo; b) meal plus aluminum hydroxide capsules; and c)
meal plus calcium carbonate powder.
As shown in Figure 3, when a placebo was given with the 320
mg phosphorus meal, 259 mg phosphorus was absorbed. If
aluminum hydroxide or calcium carbonate was ingested prior to
the meal phosphorus absorption was decreased to 198 mg and
204 mg, respectively. Each of the preparations reduced the
absorption of phosphorus significantly (P < 0.05), but there was
no significant difference between them.
Calcium intake was different on the three test days. On the
placebo test day, the calcium intake was 268 mg; on the
aluminum hydroxide test day, calcium intake was 405 mg (the
increase is due to calcium contained in the aluminum hydroxide
preparation); on the calcium carbonate test day calcium intake
increased to 1666 mg. Calcium absorption is shown on the right
side of Figure 3, and shows that calcium carbonate powder was
associated with a markedly increased average calcium absorp-
tion of 471 mg (28% of intake).
Discussion
This experimental procedure is well tolerated by dialysis
patients and by normal subjects. Since less than twenty—four
hours is required for each experiment, the procedure can be
done between regularly scheduled dialysis treatments. The
utilization of specially designed lavage fluids [7] prevents any
detectable disturbance of fluid and electrolyte balance, and no
harmful effects were noted. This lavage has no effect on colonic
mucosal histology [10]. The experimental period is short, per-
mitting continuous observation of the subjcts so as to avoid any
breaks in protocol.
Our studies on timed recovery of ingested nonabsorbable
marker (PEG), compared with the timed recovery of phospho-
rus following either a meal or fast, indicate that all unabsorbed
ingested phosphorus will be quantitatively recovered by a four
hour lavage. Therefore, the accuracy of this procedure for
measuring the absorption of ingested phosphorus will be limited
mainly by our ability to know the exact amount of ingested
phosphorus. Although the exact amount of phosphorus con-
tained in the ingested meal is impossible to measure, an
accurate estimate is obtained by preparing duplicate meals from
the same food sources which are quantitatively analyzed.
The normal subjects had a mean serum 1 ,25(OH)2-D3 level of
48 4 pg/mI. They ingested 303 mg of phosphorus and
absorbed 242 mg (80% of intake). Thus, normal subjects absorb
a greater percentage of ingested phosphorus as compared to the
absorption of ingested calcium when measured by the same
technique [6]. This percentage of phosphorus absorption is
similar to that recently reported in normal subjects by
Maierhofer et al [15]. The dialysis patients had severely de-
pressed serum levels of l,25(OH)2-D3, yet their average phos-
phorus absorption was only slightly reduced (not statistically
significant) compared to the control group. When the dialysis
patients were treated with calcitriol, 1 ,25(OH)2-D3 concentra-
tions increased above the levels found in the controls. This was
associated with an increase in phosphorus absorption from 186
mg (60% of ingested) to 272 mg (86% of ingested). From this
phase of the experiment we conclude that absorption of dietary
phosphorus is a highly efficient process in normal subjects.
Although vitamin D status does influence the absorption of
phosphorus, the effect is quantitatively small and patients who
are even severely vitamin D deficient can efficiently absorb
dietary phosphorus.
From data using standard metabolic balance methods, it is
well established that aluminum hydroxide reduces phosphorus
absorption. We have reviewed the literature and selected those
published balance studies which permit us to recalculate the
data in a format similar to that used in our protocol. (Several
other reported balance studies could not be used because the
data was inadequate for this purpose.) In order to derive data
comparable to ours, we utilized one—third of the daily balance
figures to simulate phosphorus balance per meal rather than
daily phosphorus balance. As shown in Table 5, the degree to
which aluminum hydroxide inhibited phosphorus absorption in
these studies varied from 70 to 181 mg per meal. The results in
our dialysis patients, also summarized in Table 5, revealed
aluminum hydroxide to be slightly less effective than had been
previously noted in the normal subjects, but similar to the
results previously reported in patients with chronic renal dis-
ease.
In our study aluminum, or calcium, was administered to
dialysis patients in a dose of 75 mEq, ingested immediately
prior to the meal. This dose of aluminum reduced phosphorus
absorption by 61 to 123 mg. Although the valence of phospho-
(70%)
c 3000
I :::
- 1500
'a0
-c0.
a,z 50
00
400
300
200
100
Phosphorus Calcium
(79%)
E
C0
0.
0(0
.0
cc
a,2
1(28%)
Placebo AI)OH ) Al2)C03)3 Al2(C03)3
Capsules Capsules Suspension
Fig. 2. The inhibition of phosphorus absorption by several aluminum—
containing phosphorus binding solutions. Symbol * signifies a signifi-
cant difference of equal to P < 0.01 compared with placebo.
(62%) (65%)
Placebo Al)OR)3 CaCO3
Capsules Powder
Placebo Al)OH)3 CaCO3
Capsules Powder
Fig. 3. Effect of aluminum hydroxide and calcium carbonate on net
intestinal phosphorus and calcium absorption. Symbol * signifies a
significant difference equal to P < 0.05 compared with placebo.
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Table 5. Summary of previous and current data on the effect of aluminum hydroxide on phosphorus absorption
rus, as phosphate, in the GI tract is unknown and probably
varies within the GI tract and from person to person, we
assumed a valence of 1.8 as suggested by Lennon, Lemann and
Litzow 1161. Utilizing this valence, the 61 to 123 mg of phos-
phorus presumably bound to aluminum, or calcium, represents
only between 4 and 7 mEq of phosphate. (Even if the maximal
phosphate valence of 3 is assumed, that is, P04n, then this
represents only between 6 to 12 mEq of phosphate.) it remains
unclear why aluminum and calcium antacids are such inefficient
phosphorus binders in vivo. Poor mixing of the antacid with
dietary phosphorus (a similar problem was noted with antacid
neutralization of stomach acid [171) and competition by the
intestinal mucosal absorptive mechanisms for luminal phospho-
rus are two possible reasons for this inefficiency.
Although it has been stated that aluminum carbonate binds up
to one—third more phosphorus than does aluminum hydroxide
[18], to the best of our knowledge there has been no previous in
vivo comparison of the effect of various aluminum antacids on
the absorption of dietary phosphorus. In seven dialysis pa-
tients, we found no differences between 75 mEq doses of
aluminum hydroxide and aluminum carbonate and we also
found no difference between the liquid and capsule forms of
aluminum carbonate.
Because of the hazards of aluminum toxicity in dialysis
patients [19, 20], other non-aluminum phosphorus binding
agents are being investigated. It has been suggested that cal-
cium carbonate may be a useful phosphate binding drug [21—241.
However, there is little data demonstrating how effectively
calcium carbonate binds phosphorus. Therefore, we compared
the relative effectiveness of 75 mEq of calcium carbonate
powder and 75 mEq of aluminum hydroxide in reducing dietary
phosphorus absorption in five dialysis patients. We found that
both drugs reduced phosphorus absorption to approximately
the same degree. However, it is important to note that the 75
mEq of calcium carbonate resulted in a markedly increased
calcium absorption. It is likely that the reduction in serum
phosphorus concentration noted after calcium carbonate ther-
apy is only partially due to phosphorus binding within the GI
tract. Increased calcium absorption probably results in sys-
temic calcium—phosphate deposition in bone and soft tissue.
Previous studies of oral calcium supplementation in patients
with modest renal insufficiency have demonstrated enhanced
positive phosphorus balance associated with a fall in serum
phosphorus which is probably attributable to the mechanism
[21, 22].
During calcium supplementation, 28% of the calcium load
was absorbed. This fractional absorption is greater than that
found in several prior studies [21, 22, 251. There are several
possible explanations for this discrepancy. First, in earlier
reports fecal and dietary calcium was measured using less
specific methodology, such as flame emission spectroscopy,
which suffers from major positive interference by sodium,
potassium, and phosphorous. Despite corrections, fecal cal-
cium may have been overestimated. We utilized the more
specific atomic absorption technique for calcium determination.
Second, we measured calcium absorption after a single meal. It
is possible that the gut slowly adapts to high calcium intake over
a period of weeks to months, so that the percent of calcium
absorption decreases with time as oral calcium supplementation
continues.
The phosphorus binding drugs we studied were all inefficient.
This study emphasizes the importance of dietary phosphorus
restriction in preventing phosphorus retention and metabolic
bone disease in patients with chronic renal failure. Available
drugs cannot be utilized to offset the adverse effects of a
phosphorus—rich diet. Until effective, and safe, phosphorus
binding agents can be developed, dietary phosphorus restriction
will remain an important means of preventing and treating renal
osteodystrophy.
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Reference
Subjects
(N)
Dose of aluminum
per meal
mEq
Phosphorus intake
per meal
Phosphorus absorption per meal
Control
Al(UH))3
mg
Kirsner [11] Normal (3) 44 437 288 157 131
Clarkson et al [l2] CRD (2) 82 196 69 —11 70
Clarkson et al [12]" CRD (3) 74 500 212 79 133
Cam et al [13] Normal (5) 89 430 271 116 155
Cam et al [13] CRD (2) 89 354 230 119 111
Spencer et al [14] Normal (7) 70—93 252 169 12 181
Present study Dialysis patients (7) 75 349 245 122 123
(phase l)C
Present study Dialysis patients (5) 75 320 259 198 61
(phase 2)
Difference
a CRD, chronic renal disease
Clarkson et a! [12] studied three additional patients (their cases 6, 7 and 8 in Table 2) that were not included in this table; they were excluded
because their dietary intake of phosphorus and/or their aluminum intakes were so variable that averaging these results seemed unreasonable.
Phase 1 compared the effect of various aluminum containing antacids while phase 2 compared the effect of aluminum hydroxide and calcium
carbonate. The meals were slightly different and the studies took place at different times, therefore the data was not combined.
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